title: Synthesis and biological evaluation of phenylacetyl derivatives having low central nervous system permeability as potent and selective M2 muscarinic receptor antagonists.
abstract: A series of phenylacetyl derivatives containing the 5,10-dihydro-11H-dibenzo[b,e,][1,4]diazepin-11-one or 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton was prepared and evaluated for their binding affinities to muscarinic receptors in vitro and for antagonism of bradycardia, salivation and tremor in vivo. Among them, compounds 56 and 66 had high affinity for M2 muscarinic receptors in the heart (pKi = 8.7 and 8.9, respectively) with low affinity for M3 muscarinic receptors in the submandibular gland. A structure-activity relationship (SAR) study suggested that the high M2 selectivity over the M3 muscarinic receptors of 56 may be attributed to the direction of the carboxamide carbonyl group. In in vivo studies, 56 and 66 antagonized oxotremorine-induced bradycardia in rats on both intravenous and oral administration, and their heart rate increasing effect in dogs with nocturnal bradycardia was about 3-fold greater than that of AF-DX 116. Furthermore, they had almost no influence on oxotremorine-induced tremor in mice, presenting no evidence of central transfer.
authors.affiliation: Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Kakefuda
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Takizawa
authors.forename: S
authors.initials: S
authors.lastname: Hirano
authors.forename: H
authors.initials: H
authors.lastname: Shibata
authors.forename: Y
authors.initials: Y
authors.lastname: Yamagiwa
authors.forename: I
authors.initials: I
authors.lastname: Yanagisawa
mesh_terms: D000818:Animals; D001919:Bradycardia / Q000139:chemically induced / Q000188:drug therapy; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003984:Dibenzazepines / Q000494:pharmacology; D004285:Dogs; D006321:Heart / Q000187:drug effects; D008297:Male; D051379:Mice; D018727:Muscarinic Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology; D010276:Parasympatholytics / Q000138:chemical synthesis* / Q000494:pharmacology; D010648:Phenylacetates / Q000138:chemical synthesis* / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043585:Receptor, Muscarinic M2; D043587:Receptor, Muscarinic M3; D011976:Receptors, Muscarinic / Q000187:drug effects*; D012472:Salivation / Q000187:drug effects; D013329:Structure-Activity Relationship; D013363:Submandibular Gland / Q000187:drug effects; D014202:Tremor / Q000188:drug therapy
chemical_list: D003984:Dibenzazepines; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D010648:Phenylacetates; D011725:Pyridines; D043585:Receptor, Muscarinic M2; D043587:Receptor, Muscarinic M3; D011976:Receptors, Muscarinic; C079888:BIBN 99; C084487:5-((4-(4-(diisobutylamino)butyl)-1-phenyl)acetyl)-10,11-dihydro-5H-dibenzo(b,e)(1,4)diazepin-11-one; D010890:Pirenzepine; C048593:otenzepad